Publication of 2023 financial results and operating update
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Die MorphoSys AG (FSE: MOR; NASDAQ: MOR) hat heute bekanntgegeben, dass im Rahmen eines mündlichen Vortrags neue Wirksam…
S2 Genomics and their exclusive distributor for Germany and Austria, Dunn Labortechnik, present the new Singulator™ Syst…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
The US trade magazine "Healthcare Tech Outlook" recently named ibidi GmbH one of the ten best European manufacturers of…
Das US-amerikanische Fachmagazin “Healthcare Tech Outlook“ hat ibidi GmbH kürzlich zu einem der zehn besten europäischen…
Die Heidelberg Pharma AG (FWB: HPHA), ein klinischer Entwickler von innovativen Antikörper-Wirkstoff-Konjugaten (ADCs),…